VIM and endometrial cancer: The progestogen medroxyprogesterone acetate has also been shown to decrease migration, invasion, and vimentin expression in endometrial cancer cells expressing progesterone receptor B or progesterone receptors A and B, though not in those expressing progesterone receptor A alone.